Neurogene Inc. (NGNE) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
NGNE currently has 15.8M outstanding shares. with significant dilution risk as 23.3M authorized shares could dilute existing holders by 147.3%. The company has significantly diluted shareholders by 25.44% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 15.8M shares outstanding |
16M | 23M |
| Mar 24, 2026 |
10-K filing | 15.6M shares outstanding |
16M | 24M |
| Nov 13, 2025 |
10-Q filing | 15.5M shares outstanding |
15M | 24M |
| Aug 11, 2025 |
10-Q filing | 14.3M shares outstanding |
14M | 25M |
| May 09, 2025 |
10-Q filing | 14.3M shares outstanding |
14M | 25M |
| Mar 24, 2025 |
POS AM filing: This POS AM filing relates to the offering of 4,000,042 shares of common stock by selling stockholders, which includes 2,165,042 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants held by certain of the Selling Stockholders. |
15M | 24M |
| Mar 24, 2025 |
S-3 filing: The filing is an S-3 shelf registration for the potential issuance of up to $300,000,000 of various securities including common stock, preferred stock, debt securities, warrants and/or units. |
15M | 24M |
| Mar 24, 2025 |
10-K filing | 14.9M shares outstanding |
15M | 24M |
| Dec 02, 2024 |
S-1 filing: An S-1 filing indicating future sales of shares by existing stockholders could cause the stock price to decline. The offering includes 4,000,042 shares of common stock to be offered by selling stockholders, which includes 2,165,042 shares of common stock issuable upon the exercise of pre-funded warrants. |
15M | 7.1M |
| Nov 18, 2024 |
10-Q filing | 14.9M shares outstanding |
15M | 3.1M |
| Aug 09, 2024 |
10-Q filing | 13.0M shares outstanding |
13M | 5M |
| May 10, 2024 |
10-Q filing | 13.0M shares outstanding |
13M | 5M |
| Mar 18, 2024 |
10-K filing | 12.9M shares outstanding |
13M | 5.1M |
| Nov 14, 2023 |
10-Q filing | 9.4M shares outstanding |
9.4M | 8.6M |
| Sep 25, 2023 |
Stock Split
8-K filing: Stock split 1-for-5 | Outstanding: 44,021,429 → 8,805,285 |
8.8M | 9.2M |
| Aug 10, 2023 |
10-Q filing | 44.0M shares outstanding |
44M | 46M |
| May 08, 2023 |
10-Q filing | 42.8M shares outstanding |
43M | 47M |
| Mar 20, 2023 |
10-K filing | 42.8M shares outstanding |
43M | 47M |
| Nov 14, 2022 |
10-Q filing | 42.6M shares outstanding |
43M | 47M |
| Aug 09, 2022 |
10-Q filing | 42.6M shares outstanding |
43M | 47M |
| May 09, 2022 |
S-3 filing: Neoleukin Therapeutics, Inc. is registering 15,309,270 shares of common stock for resale by the selling stockholder. |
42M | 47M |
| May 09, 2022 |
10-Q filing | 42.5M shares outstanding |
43M | 47M |
| Mar 01, 2022 |
10-K filing | 42.5M shares outstanding |
42M | 32M |
| Nov 04, 2021 |
10-Q filing | 42.4M shares outstanding |
42M | 32M |
| Aug 05, 2021 |
10-Q filing | 42.4M shares outstanding |
42M | 32M |
| May 12, 2021 |
10-Q filing | 42.3M shares outstanding |
42M | 32M |
| Mar 25, 2021 |
10-K filing | 42.3M shares outstanding |
42M | 32M |
| Dec 11, 2020 |
S-3 filing: Neoleukin Therapeutics, Inc. is offering Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units for a total aggregate amount of $400,000,000. |
42M | 33M |
| Nov 09, 2020 |
10-Q filing | 41.9M shares outstanding |
42M | 0 |
| Aug 12, 2020 |
10-Q filing | 41.7M shares outstanding |
42M | 0 |
| May 06, 2020 |
10-Q filing | 38.5M shares outstanding |
38M | 0 |
| Mar 12, 2020 |
10-K filing | 38.4M shares outstanding |
38M | 0 |